CPT® Code 80363

1. Indications

The laboratory test represented by CPT® Code 80363 is indicated for the detection and quantification of opioids and opiate analogs in patients who may be experiencing issues related to opioid use. This includes, but is not limited to, the following conditions:

• Substance Abuse Evaluation This test is often utilized in the assessment of individuals suspected of opioid misuse or abuse, providing critical information regarding their substance use history.
• Monitoring Treatment Patients undergoing treatment for opioid dependence or those prescribed opioid medications may be tested to ensure compliance with their treatment regimen and to monitor for potential misuse.
• Clinical Diagnosis The test may be indicated in clinical settings where the presence of opioids is relevant to the patient's symptoms or medical history, aiding in the diagnosis of conditions related to opioid use.

2. Procedure

The procedure for conducting the test associated with CPT® Code 80363 involves several key steps to ensure accurate and reliable results. First, a blood sample is obtained through a process known as venipuncture, where a needle is inserted into a vein to collect the necessary serum or plasma. This step is crucial as it provides a direct measure of opioids present in the bloodstream. Next, a urine sample is collected, which can be done either through random voiding by the patient or via catheterization if necessary. This method allows for the detection of opioids that may have been metabolized and excreted through the urine. Additionally, in cases where meconium stool is required, it is collected from a diaper, particularly in newborns, to assess exposure to opioids during gestation. Once the samples are collected, they are subjected to quantitative liquid chromatography-tandem mass spectrometry, a highly sensitive and specific analytical technique that separates and quantifies the various opioids and opiate analogs present in the samples. This comprehensive testing approach ensures that a wide range of substances can be accurately identified and measured, providing valuable information for clinical decision-making.

3. Post-Procedure

After the procedure, there are no specific post-procedure care requirements for patients, as the sample collection is minimally invasive. However, it is essential for healthcare providers to communicate the expected timeline for results, which may vary depending on the laboratory's processing capabilities. Patients may be advised to follow up with their healthcare provider to discuss the results of the test and any necessary actions based on the findings. Additionally, if the test is part of a broader treatment or monitoring plan, ongoing assessments may be scheduled to ensure continued compliance and to address any emerging issues related to opioid use.